In the absence of alternative biochemical PCa biomarkers, the majority of PCa screening guidelines still advise the measurement of total serum PSA (tumor (t)PSA>4 ng/mL) as a benchmark marker for the detection of PCa. This evidence concerns the gene KLK3 and posterior cortical atrophy.